Table 1.
Clinical characteristics of 28 MM patients.
| Baseline characteristics | n (%) |
|---|---|
| Age | |
| >65 | 11 (39%) |
| ≤65 | 17 (61%) |
| Gender | |
| Male | 20 (71%) |
| Female | 8 (29%) |
| Type | |
| IgG | 12 (42%) |
| IgA | 7 (25%) |
| Light chain | 9 (33%) |
| DS stage | |
| I | 0 |
| II | 5 (17%) |
| III | 23 (83%) |
| ISS stage | |
| I | 6 (21%) |
| II | 10 (35%) |
| III | 12 (44%) |
| LDH | |
| Normal | 3 (10%) |
| >Normal | 25 (90%) |
| β2-MG (mg/L) | |
| <5.5 | 18 (64%) |
| ≥5.5 | 10 (36%) |
| Albumin (g/L) | |
| <35 | 16 (27%) |
| ≥35 | 12 (73%) |
| Creatinine (mmol/L) | |
| >177 | 2 (7%) |
| ≤177 | 26 (93%) |
| Ca2+ (mmol/L) | |
| ≤2.75 | 24 (86%) |
| >2.75 | 4 (14%) |
DS, Durie–Salmon; ISS, International Staging System; LDH, lactate dehydrogenase.